Results 271 to 280 of about 3,155,563 (287)

No Observable Adverse Effect Level (NoAEL)

2015
openaire   +1 more source

Incidence and Preventability of Adverse Drug Events Among Older Persons in the Ambulatory Setting

JAMA - Journal of the American Medical Association, 2003
Leslie R Harrold, Jeffrey Rothschild, Andrew C Seger   +2 more
exaly  

Managing adverse effects and drug–drug interactions of antiplatelet agents

Nature Reviews Cardiology, 2011
A Michael Lincoff, Lincoff A Michael
exaly  

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

JAMA Oncology, 2019
Yucai Wang, Fang Yang, Ashish V Chintakuntlawar   +2 more
exaly  

Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention

Ca-A Cancer Journal for Clinicians, 2017
Manuel Picon-Ruiz, Cynthia Morata-Tarifa, Joyce M Slingerland   +2 more
exaly  

US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014

JAMA - Journal of the American Medical Association, 2016
Nadine Shehab, Maribeth C Lovegrove, Andrew I Geller   +2 more
exaly  

National Surveillance of Emergency Department Visits for Outpatient Adverse Drug Events

JAMA - Journal of the American Medical Association, 2006
Daniel S Budnitz, Daniel A Pollock, Aaron B Mendelsohn   +2 more
exaly  

Late adverse effects of treatment among patients cured of cancer during childhood

Ca-A Cancer Journal for Clinicians, 1992
exaly  

Medication-Attributed Adverse Effects in Placebo Groups

Archives of Internal Medicine, 2006
Winfried Rief, Arthur J Barsky
exaly  

4.4 The proposed replacement of the no observed adverse effect level with benchmark dose levels in food risk assessment

Human & Experimental Toxicology, 2009
openaire   +2 more sources